Psilocybin and Cancer Care: Promising Research, Important Questions

A cancer diagnosis can change how a person thinks about everything: their health, their family, their future, and the time they have together. Medical treatment addresses the disease, but emotional and existential distress can need care of its own.

That is one reason researchers are studying psilocybin-assisted therapy for people affected by cancer. Early results are encouraging, particularly for depression and anxiety. They also raise practical questions: Who might be eligible? What does a supervised session involve? And how should a nurse respond when a patient asks about it?

A recent Oncology Nursing News interview with oncologist Jason Konner, MD puts those questions in the hands of the people most likely to hear them first: oncology nurses and other frontline care professionals.

What is psilocybin-assisted therapy in cancer care?

In the studies discussed here, psilocybin is given as part of a structured clinical intervention. Participants are screened beforehand, supported during the experience, and given opportunities afterward to discuss and process it. Researchers are examining whether that approach can ease depression, anxiety, and distress associated with a serious illness.

Psilocybin is not a treatment for cancer itself. The clinical question is whether psilocybin-assisted therapy may improve aspects of a patient’s psychological well-being and quality of life.

That distinction matters. A clinical trial with screening and trained support cannot be reduced to “take mushrooms and see what happens.” Konner emphasizes the importance of a safe setting and support, including when an experience becomes challenging.

What does the research show so far?

Two randomized trials published in 2016 found substantial reductions in depression and anxiety symptoms among participants with life-threatening cancer after psilocybin-assisted treatment. More recent research has explored group-based therapy for people with cancer and major depressive disorder. These findings give researchers a strong reason to continue studying the approach, but the studies have generally been small and their results do not establish that it is appropriate for every patient.

A 2025 randomized phase 2b trial involving adults with life-threatening illnesses also reported greater improvements in several depression and anxiety measures with psilocybin-assisted psychotherapy than with its comparison treatment at six to seven weeks. That population was broader than cancer patients alone, so its findings should not be presented as a cancer-specific result.

The evidence is promising. It is still developing. Researchers need to learn more about which patients benefit, how durable the benefits are, and how to deliver care safely across different clinical settings.

Why are oncology nurses part of this conversation?

Patients do not save every difficult question for the oncologist. A nurse may be the person a patient trusts enough to ask, “I heard psilocybin might help with the fear. Is that true?”

A useful response begins with curiosity rather than a sales pitch or a dismissal. What has the patient heard? Are they asking about a clinical trial, considering an unsupervised experience, or struggling with depression or anxiety right now? Those answers help the care team address the patient’s actual needs.

Nurses and other clinicians can also help patients understand the difference between an investigational therapy under clinical supervision and claims they encounter online. As Konner’s interview makes clear, psychedelic literacy includes knowing the potential benefits and recognizing the need for screening, support, and follow-up.

What safety questions matter?

A patient’s medical history, mental health history, medications, and support system all matter when evaluating participation in psychedelic research. Konner specifically raises concerns about a history of psychosis or mania, certain cardiovascular conditions, uncontrolled high blood pressure, seizure disorders, and lithium use. These are reasons for careful assessment by qualified clinicians, not a checklist for patients to clear on their own.

The experience itself may also be emotionally difficult. The FDA’s guidance for psychedelic clinical investigations reflects the need to study these drugs within carefully designed protocols that account for their distinctive effects and risks. Patients should discuss any interest in a trial with their oncology team and the trial investigators. They should not stop prescribed medication to pursue psilocybin.

Could psilocybin also help with chemotherapy-related nerve pain?

This is an intriguing research question, but there is no established clinical evidence that psilocybin prevents chemotherapy-induced peripheral neuropathy in patients. In the Oncology Nursing News interview, Konner discusses emerging preclinical work. Preclinical findings can guide future studies; they cannot tell a person undergoing chemotherapy that a treatment is proven to protect their nerves.

The same care applies to other possible uses, including support for caregivers and clinicians experiencing grief or burnout. Interest is growing, but each proposed use needs evidence of its own.

The takeaway for patients and families

Psilocybin-assisted therapy may eventually become another way to support some people living with cancer. For now, the most responsible message is both hopeful and precise: clinical studies have found encouraging mental health results, while safety, access, and patient selection remain active areas of research.

If cancer-related anxiety, depression, or fear is affecting your life, tell your oncology team. You deserve support now, whether or not a psychedelic clinical trial is available or appropriate for you.

At Learn Euphoria, we believe better conversations start with better information. For the clinical perspective that inspired this article, read the original Oncology Nursing News interview with Dr. Jason Konner.

This article is educational and is not medical advice. Psilocybin-assisted therapy remains investigational for the uses discussed here; consult your healthcare team about treatment decisions.